Saxenda (Liraglutide): The Original Weight-Loss GLP-1 (2026)
Saxenda is liraglutide — a daily-injection GLP-1 approved for chronic weight management since 2014. Mechanism, dosing, trial results, side effects and where it fits in 2026.
Saxenda is the original GLP-1 receptor agonist approved for chronic weight management. The active ingredient is liraglutide — the same molecule sold under Victoza for type 2 diabetes. Saxenda's claim to fame: it broke the path that Wegovy and Zepbound followed nearly a decade later.
So Saxenda still has a place in 2026 — when it's the right answer, what to expect, and how it compares to the newer weekly options.
What Saxenda is
| Aspect | Detail |
|---|---|
| Brand | Saxenda |
| Active ingredient | Liraglutide |
| Class | GLP-1 receptor agonist (single) |
| Maker | Novo Nordisk |
| FDA approval (weight) | 2014 |
| Form | Daily subcutaneous injection |
| Doses | 0.6 / 1.2 / 1.8 / 2.4 / 3.0 mg |
| Maintenance dose | 3.0 mg/day |
| Half-life | ~13 hours |
Same molecule as Victoza (approved for T2D in 2010), just at the higher 3.0 mg/day dose for weight management.
How Saxenda works
Saxenda is a GLP-1 receptor agonist. It mimics the GLP-1 hormone the body releases after meals, doing what every drug in the class does:
- Slows gastric emptying — extends satiety
- Reduces appetite via central nervous system effects
- Stimulates glucose-dependent insulin release
- Suppresses glucagon
The shorter half-life (~13 hours) is why it's dosed daily, unlike the weekly options.
For mechanism details, see GLP-1 receptor agonists.
What the trials show
The pivotal trial: SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence), a 56-week study of 3,731 adults with BMI ≥27 plus a weight-related condition, or BMI ≥30.
Key results at the 3.0 mg/day dose:
| Outcome | Saxenda | Placebo |
|---|---|---|
| ≥5% body weight lost | 63% of patients | 27% |
| ≥10% body weight lost | 33% of patients | 11% |
| ≥20% body weight lost | 14% of patients | 3% |
| Average weight loss | ~8% body weight | ~2.6% |
Of patients who responded (lost ≥5% by 16 weeks), 85% maintained clinically meaningful weight loss at 56 weeks.
A 3-year SCALE extension study showed:
- 56% lost ≥5% body weight at year 1
- About half of those maintained the loss at year 3 on continued treatment
Dosing
Saxenda titration is weekly:
| Week | Dose |
|---|---|
| 1 | 0.6 mg/day |
| 2 | 1.2 mg/day |
| 3 | 1.8 mg/day |
| 4 | 2.4 mg/day |
| 5+ | 3.0 mg/day (target maintenance) |
Each step is intended to manage gastrointestinal side effects. Most patients reach 3.0 mg within ~5 weeks.
Storage: Refrigerate unused pens (36-46°F) until expiration. Once in use, store at room temperature (59-86°F) or refrigerated, up to 30 days. Never freeze.
Missed dose: Take the next regularly scheduled dose at the usual time. Do not double dose.
Side effects
Same general GLP-1 profile, with daily dosing intensifying the early GI burden for some patients:
- Common: Nausea, vomiting, diarrhea, constipation, headache, fatigue, indigestion, low blood sugar (in T2D patients), injection- site reactions, dizziness
- Less common: Gallbladder issues, kidney function changes
- Rare: Pancreatitis, thyroid C-cell tumors (boxed warning, rodent data), severe allergic reactions
Full safety profile: GLP-1 side effects.
When Saxenda is the right answer
The newer weekly drugs (Wegovy, Zepbound) produce more weight loss on average. But Saxenda has real niches in 2026:
- Daily-injection preference. Some patients prefer a daily routine to a weekly cliff.
- Shorter half-life if you need to stop quickly. Liraglutide clears the body within 2-3 days; semaglutide and tirzepatide take weeks.
- Older patients or polypharmacy. Some prescribers prefer the predictability of a shorter-acting drug when titrating around other medications.
- Supply constraints. When Wegovy or Zepbound is on shortage, Saxenda may be more accessible.
- Pediatric approval. Saxenda is FDA-approved for adolescents (12-17 years) with obesity and body weight ≥132 lb.
Saxenda vs Wegovy
Both are Novo Nordisk GLP-1s for weight management:
| Saxenda | Wegovy | |
|---|---|---|
| Active | Liraglutide | Semaglutide |
| Dosing | Daily | Weekly |
| Half-life | ~13 hours | ~7 days |
| Average weight loss | ~8% | ~15% |
| Approved year | 2014 | 2021 |
| Pediatric approval | ≥12 yr | ≥12 yr |
| Cost | ~$1,349 list | ~$1,349 list |
For most adults seeking maximum weight loss, Wegovy is the stronger choice. Saxenda is the right call for the niches above.
Saxenda vs Zepbound
| Saxenda | Zepbound | |
|---|---|---|
| Class | Single GLP-1 | Dual GLP-1/GIP |
| Average weight loss | ~8% | ~21% |
| Maker | Novo Nordisk | Eli Lilly |
| Dosing | Daily | Weekly |
| Approved year | 2014 | 2023 |
Zepbound substantially outperforms Saxenda on average weight loss.
Cost
- List price: ~$1,349/month
- With Novo Nordisk savings card + commercial insurance: as low as $25/copay (eligibility caps apply)
- Without insurance: Less aggressive direct-cash programs than for Wegovy; pricing varies by pharmacy
See GLP-1 cost and GLP-1 coupon.
Who shouldn't take Saxenda
- Personal or family history of medullary thyroid carcinoma or MEN-2
- Personal history of pancreatitis
- Severe gastroparesis
- Pregnancy or planning pregnancy
- Active eating disorder
- Type 1 diabetes (Saxenda is not appropriate)
FAQ
Is Saxenda the same as Victoza? Same active ingredient (liraglutide), different dose and indication. Saxenda goes to 3.0 mg/day for weight management; Victoza maxes at 1.8 mg/day for diabetes.
Is Saxenda a GLP-1? Yes — Saxenda is a GLP-1 receptor agonist.
How much weight will I lose on Saxenda? Average is about 8% body weight at the 3.0 mg dose over 56 weeks. Individual results vary.
Why is Saxenda dosed daily when Wegovy is weekly? Liraglutide has a much shorter half-life (~13 hours) than semaglutide (~7 days). Each is engineered for its specific pharmacokinetics.
Is Saxenda approved for teens? Yes — FDA-approved for adolescents 12-17 years with body weight ≥132 lb and obesity.
This article is for educational purposes only and is not medical advice. Discuss treatment decisions with a qualified healthcare professional.